Chronic Lymphocytic Lymphoma, Issue 2, 2019 — Part 2: Our
interview with Dr Woyach highlights the following topics as well as
cases from her practice:
Recent data and evolution of the front-line treatment paradigm
for patients with CLL (00:00)
Evaluation of MRD and implications for therapy (03:50)
Efficacy and tolerability of first-line regimens for CLL
(06:14)
Perspective on the role of chemoimmunotherapy for patients with
CLL (08:41)
Case: A woman in her mid-70s experiences a
dramatic response after receiving ibrutinib as first-line therapy
for CLL (10:48)
Bleeding and arthralgias associated with ibrutinib (12:14)
Rates of discontinuation and the role of dose reduction to
mitigate side effects in patients receiving ibrutinib (14:45)
Incidence and management of opportunistic infections during
ibrutinib treatment (18:11)
Role of chimeric antigen receptor (CAR) T-cell therapy in CLL;
effect of ibrutinib on CAR T-cell generation and efficacy
(21:54)
Case: A man in his late 60s with CLL receives
acalabrutinib on a clinical trial after developing atrial
fibrillation on ibrutinib therapy (24:01)
Therapeutic approach for patients who develop resistance to BTK
inhibitors (27:19)
Understanding the C481S mutation as a mechanism of resistance
to ibrutinib and acalabrutinib (30:47)
Targeting the C481S mutation to overcome resistance to BTK
inhibitors (32:06)
Case: A woman in her mid-60s with del(17p) CLL
and no IGHV mutation receives venetoclax after disease progression
on multiple lines of therapy (36:11)
Prophylactic measures to prevent venetoclax-associated tumor
lysis syndrome (38:25)
Emerging data with the combination of ibrutinib and venetoclax
for CLL (40:04)
Activity and tolerability of PI3 kinase inhibitors for patients
with CLL (44:17)
Acalabrutinib with obinutuzumab for treatment-naïve and
relapsed/refractory CLL (47:51)
Incidence and spectrum of second cancers among patients with
CLL receiving BTK inhibitors (49:51)
Case: A man in his early 70s develops RT to
DLBCL after receiving ibrutinib as first-line therapy for CLL
(51:00)
Prognosis and management of RT (53:38)
Role of immune checkpoint inhibitors and CAR T-cell therapy in
the management of RT (56:37)
Ongoing Phase III EA9161 and Alliance A041702 studies
evaluating the addition of venetoclax to ibrutinib with
obinutuzumab for patients with CLL (59:21)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.